Outcomes of epilepsy surgery in patients with diffuse gliomas of the brain
- 24 July 2024
- journal article
- Published by Medical Informational Agency Publishers in Russian neurological Journal
- Vol. 29 (3) , 49-57
Abstract
The objectives of surgical treatment of patients with diff use brain gliomas include achieving control over epileptic seizures and improving quality of life, in addition to prolonging relapse-free period and life duration. The aim of the research is to study the factors that determine the eff ectiveness of epilepsy surgery in patients with diffuse brain gliomas. Material and methods. The study group comprised 104 patients with diff use brain gliomas, aged 41.21 ± 14.74. Results of author’s research. Clinical, neuroimaging and morphological factors were studied. Of the studied group of 104 patients with diffuse brain gliomas who had been diagnosed with epilepsy prior to surgery, the remission of 6 months after surgery was achieved in 58 (55.77 %) patients and of 12 months in 55 (52.88 %) patients. The development of acute symptomatic epileptic seizures (p = 0.68067) and acute symptomatic status epilepticus (p = 0.41626) in post-operative period do not determine the outcomes of epilepsy surgery. Neither the histological subtype of the diffuse brain gliomas, nor the molecular-genetic factor (IDH1/2 mutation, 1p/19q codeletion) determines the outcomes of epilepsy surgery in this patient category. The group of antiepileptic medications or the medication regimen (monotherapy, two-drug therapy) also does not determine the surgery outcomes. The factors that determine a favorable outcome of surgical treatment for epilepsy in patients with diff use brain gliomas are complete tumor removal and involvement of brain commissures after magnetic resonance imaging before surgery. Conclusion. The effectiveness of epilepsy surgery is determined by the radical removal of the diff use brain glioma, thereby eliminating the glutamate-mediated mechanisms of epileptogenesis.Keywords
This publication has 17 references indexed in Scilit:
- Postoperative risk of IDH mutant glioma–associated seizures and their potential management with IDH mutant inhibitorsJournal of Clinical Investigation, 2023
- Glioma features and seizure control during long-term follow-upEpilepsy & Behavior Reports, 2023
- Predictors of seizure outcomes in patients with diffuse low‐grade glioma‐related epilepsy after complete glioma removalCNS Neuroscience & Therapeutics, 2022
- Seizure outcome in temporal glioblastoma surgery: lobectomy as a supratotal resection regime outclasses conventional gross-total resectionJournal of Neuro-Oncology, 2021
- Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure controlSeizure: European Journal of Epilepsy, 2019
- Risk factors for injury in a community‐treated cohort of patients with epilepsy in AustraliaEpilepsia, 2019
- Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological studyNeuro-Oncology, 2011
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Temporal lobe tumoral epilepsyNeurology, 2003
- Proposal for a New Classification of Outcome with Respect to Epileptic Seizures Following Epilepsy SurgeryEpilepsia, 2001